Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content
Vanishsrs2.png

Following the publication of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) paper “Transcriptomic Signatures in Sepsis and a Differential Response to Steroids: From the VANISH Randomized Trial

https://www.atsjournals.org/doi/abs/10.1164/rccm.201807-1419OC  PubMed: 30365341

We have demonstrated that sepsis response signatures (SRS)/sepsis endotypes are associated with different responses to treatment. Genome-wide gene expression profiling was performed and SRS endotype was determined using a previously established model with seven discriminant genes. We concluded that transcriptomic profile at onset of septic shock was associated with response to corticosteroids. Those with the immuno-competent SRS2 endotype had significantly higher mortality when given corticosteroids compared to placebo.